Evidence map›Paper›PMID 42353155›Full record

ArticleInternational journal of molecular sciences2026

Early Combined B-Cell Depletion and BTK Inhibition Reduced TLS-like Structures and Relapse in PLP

Xiujuan Lang, Lin Fu, Feifei Tang, Miao Hao, Jiurong Liu, Zhengyi Chen, Wei Huang, Yue Sun, Yanting Meng, Yanping Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiujuan LangDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.ORCID 0009-0003-5134-1868
Lin FuDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Feifei TangDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Miao HaoDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Jiurong LiuDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Zhengyi ChenDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Wei HuangDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Yue SunCenter for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin 150081, China.
Yanting MengDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Yanping WangDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Yumei LiuDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Xijun LiuDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Bo SunDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
Hulun LiDepartment of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.

Funding

National Natural Science Foundation of China 82271845National Natural Science Foundation of China 82371821
6 · The paper itself

Abstract

B-cell-depleting therapies have revolutionized multiple sclerosis (MS) treatment, yet relapses persist in some patients-suggesting additional pathogenic drivers beyond peripheral B cells. Tertiary lymphoid structures (TLS) are extensively documented in progressive MS at autopsy, but whether their formation begins during the relapsing-remitting phase and how they evolve during the transition to progression remain undefined. Here, using the relapsing-remitting PLP

Indexed as

Agammaglobulinaemia Tyrosine KinaseB-LymphocytesEncephalomyelitis, Autoimmune, ExperimentalLymphocyte DepletionProtein Kinase InhibitorsAnimalsMiceMice, Inbred C57BLMicrogliaRecurrenceAgammaglobulinaemia Tyrosine KinaseBtk protein, mouseProtein Kinase Inhibitorsanti-CD20evobrutinibmultiple sclerosistertiary lymphoid structures

Identifiers

PMID42353155
PMCPMC13299241

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.